ProQR is recruiting people with Fuchs endothelial corneal dystrophy for a clinical study of an investigational RNA therapy. Learn more about the study and how to participate.
QR-504a is an investigational RNA therapy that aims slow down vision loss in people with TCF4 associated Fuchs endothelial corneal dystrophy (FECD). Learn more about the treatment and clinical trials.
Phase 2/3 pivotal Illuminate trial of sepofarsen for LCA10 enrollment complete with top-line data anticipated in H1 2022; Brighten pediatric trial of sepofarsen to begin in 2021; additional data from Phase 1/2 InSight extension study to be reported in
Illuminate Phase 2/3 trial of sepofarsen expected to complete enrollment in Q1 2021; additional data from Phase 1/2 InSight extension study to be reported in H2 2021
Enrollment completed for QR-421a dosing cohorts and data from next Phase 1/2 interim
… of sepofarsen for Leber Congenital Amaurosis 10 (LCA10), QR-421a for Usher syndrome and non-syndromic retinitis pigmentosa (nsRP), and QR-1123 for autosomal dominant retinitis pigmentosa (adRP) … trial is ongoing with initial data on track for 2021. QR-504a for Fuchs Endothelial Corneal Dystrophy (FECD): All …
… sepofarsen for CEP290 -mediated LCA10 on track for H1 2022 QR-421a pivotal Sirius and Celeste Phase 2/3 trials in Usher … 2021 Initial clinical data from Phase 1/2 Aurora trial of QR-1123 for autosomal dominant retinitis pigmentosa expected … our fourth pipeline program for a genetic eye disease, QR-504a for Fuchs endothelial corneal dystrophy.” Business …
… 2/3 Sirius and Celeste clinical trials of ultevursen (QR-421a) in Usher syndrome and retinitis pigmentosa underway; … planned by year-end 2022 Repeated dose study planned for QR-1123 for autosomal dominant retinitis pigmentosa and … from molecular proof-of concept biomarker study for QR-504a for Fuchs endothelial corneal dystrophy to be reported …
… trial getting underway and expected to enroll 10 patients. QR-421a for USH2A -mediated Usher syndrome and retinitis … tomography (OCT) retinal imaging, after a single dose of QR-421a. QR-421a was observed to be well tolerated with no … dose P hase 2 trial with doses up to 300 μg in 2022. QR-504a for TCF4 -mediated Fuchs Endothelial Corneal Dystrophy …
… upfront and equity and up to $1.25 billion in milestones QR-421a Phase 2/3 Sirius and Celeste trials in Usher syndrome … as anticipated. We expect to start two Phase 2/3 trials of QR-421a in Usher syndrome and nsRP before the end of the … an update from our QR-1123 program in adRP and our QR-504a Fuchs Focus trial is open for enrollment, representing …
… data reported from the Phase 1/2 clinical trial of QR-421a for the treatment of Usher syndrome and non-syndromic … trial of sepofarsen, reporting positive clinical data for QR-421a, and strengthening our financial position with a … for LCA10. Our fourth ophthalmology pipeline program, QR-504a for Fuchs endothelial corneal dystrophy, is expected to …
